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Edited by Vladimir SkulachevAbstract Cyclopentenone prostaglandins (cyPG) with antiin-
ﬂammatory and antiproliferative properties have been envisaged
as leads for the development of therapeutic agents. Because
cyPG eﬀects are mediated in part by the formation of covalent
adducts with critical signaling proteins, it is important to assess
the speciﬁcity of this interaction. By using biotinylated deriva-
tives of 15-deoxy-D12,14-PGJ2 (15d-PGJ2-B) and PGA1
(PGA1-B) we herein provide novel evidence for the diﬀerential
selectivity of protein modiﬁcation by distinct cyPG. The marked
quantitative and qualitative diﬀerences in the binding of 15d-
PGJ2-B and PGA1-B to cellular proteins were related to a diﬀer-
ential reactivity in the presence of glutathione (GSH), both
in vitro and in intact cells. Therefore GSH levels may inﬂuence
not only the intensity but also the speciﬁcity of cyPG action.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Cyclopentenone prostaglandins (cyPG) are eicosanoids
which display varied biological activities, ranging from antiin-
ﬂammatory eﬀects to inhibition of cell proliferation and viral
replication. Recently, these compounds have been the subject
of considerable interest due to their potential use as therapeu-
tic agents [1,2]. In vivo studies have shown beneﬁcial eﬀects of
cyPG in several models of inﬂammation and tissue injury [3,4].
These eicosanoids exert their actions through complex mecha-
nisms not completely elucidated. Some cyPG can act as ago-
nists of the PPAR transcription factors [5]. In addition,
cyPG can form covalent adducts with cellular thiols, both in
glutathione (GSH) and in proteins, due to the presence of an
unsaturated carbonyl group in the cyclopentenone moiety
which confers a strong electrophilicity to neighboring carbons.
Several protein targets for cyPG addition have been identiﬁed.
Modiﬁcation of functionally important sulfhydryl groups inAbbreviations: cyPG, cyclopentenone prostaglandin; 15d-PGJ2-B,
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prostanoids. Binding of cyPG to transcription factors NF-jB
and AP-1 [6,7] inhibits DNA binding. Modiﬁcation of cysteine
residues in IKK [8], thioredoxin and thioredoxin reductase
[9,10] also leads to inhibitory eﬀects. In contrast, modiﬁcation
of H-Ras proteins correlates with activation of Ras-dependent
pathways [11] and binding of cyPG to the protein Keap-1 re-
sults in activation of the transcription factor Nrf-2 and induc-
tion of genes involved in antioxidant defense [12].
Although the structure–activity relationship of cyPG has
been addressed in several studies, little is known about the
speciﬁcity of protein modiﬁcation by these compounds. We
and others have reported that protein modiﬁcation by cyPG
does not occur randomly, but aﬀects deﬁned cysteine residues
within certain proteins [12,13]. It has been proposed that a low
pH in the vicinity of the adduct may contribute to stabilize the
C–S bond [1,14]. The reactivity of thiols can also be aﬀected by
steric factors. Therefore, structural determinants of either the
protein or the cyPG may be important for the speciﬁcity of
protein modiﬁcation. We hypothesized that cyPG with diverse
structure could selectively modify distinct protein targets in
cells and/or modify some common targets with diﬀerent po-
tency. Characterization of the selectivity of protein modiﬁca-
tion by cyPG with diﬀerent structure could then provide
valuable information on the mechanism of action of these
compounds and potentially aid in the design of cyPG targeting
speciﬁc proteins. In this work we show the existence of com-
mon and selective targets for modiﬁcation by biotinylated
15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2-B) and biotinyla-
ted prostaglandin A1 (PGA1-B) in NIH-3T3 ﬁbroblasts and
explore the factors involved in diﬀerential selectivity.2. Materials and methods
2.1. Materials
15-Deoxy-D12,14-prostaglandin J2 was from Calbiochem-Novabio-
chem (San Diego, CA) and from Cayman Chemical (Ann Arbor,
MI). Biotinylated 15d-PGJ2 was the generous gift of Dr. F. J. Can˜ada
(Madrid, Spain). Biotinylated PGA1 (N-9-oxo-15S-hydroxy-prosta-
10,13E-1-dien-1-oyl-N-biotinoyl-1,5- diaminohexane) was from Cay-
man Chemical.2.2. Incorporation of biotinylated cyPG into NIH-3T3 proteins
NIH-3T3 cells were grown in DMEM (Invitrogen) containing 10%
fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 lg/
ml streptomycin. For treatments, cells were incubated with biotinyla-
ted cyPG for 2 h in serum-free medium. Cell lysates were obtainedation of European Biochemical Societies.
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EGTA, 0.1 mM b-mercaptoethanol, 0.5% SDS, 0.2 mM sodium vana-
date, 50 mM FNa containing 2 lg/ml of each of the protease inhibi-
tors: leupeptin, pepstatin A, and aprotinin and 1.3 mM Pefablock
(Boehringer), as described [13]. Protein concentration was determined
by the BCA assay (Pierce). Fifteen lg of protein from each experimen-
tal condition were electrophoresed on 12.5% polyacrylamide gels and
transferred to Immobilon-P membranes (Millipore, Bedford, MA).
In addition, 100 lg of protein were analyzed by 2D-electrophoresis
as described [13]. Incorporation of biotinylated cyPG into proteins
was assessed by Western blot and detection with horseradish peroxi-
dase-conjugated streptavidin and ECL, as described [7].
2.3. Binding of biotinylated cyPG to proteins in vitro
Formation of covalent adducts of biotinylated cyPG with proteins
in vitro was explored by using total lysates from NIH-3T3. Aliquots
from cell lysates containing 6 lg of protein were incubated with biotin-
ylated cyPG for 1 h at r.t. and analyzed by Western blot.Fig. 1. Binding of 15d-PGJ2-B and PGA1-B to proteins in NIH-3T3
ﬁbroblasts. (A) Structure of the biotinylated cyPG used in this study.
(B) Cells were incubated with the indicated concentrations of biotin-
ylated cyPG. Incorporation of the biotin label was assessed by Western
blot as described in Section 2. Labeling intensity was estimated by
image scanning of the blots. Results are average values ± S.E.M from
four independent experiments.3. Results
3.1. Modiﬁcation of NIH-3T3 proteins by 15d-PGJ2-B and
PGA1-B
The dienone 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2)
and the single enone PGA1 are the most widely used cyPG
in biological studies. Both eicosanoids have been reported to
exert antiinﬂammatory and antiproliferative eﬀects [6,8,15].
Here we have used biotinylated derivatives of 15d-PGJ2
(15d-PGJ2-B) and PGA1 (PGA1-B) (see Fig. 1A) to explore
the existence of protein targets that could be selectively modi-
ﬁed by either cyPG. Both compounds were cell permeable and
formed adducts with proteins which were resistant to electro-
phoresis under reducing conditions (Fig. 1B). Interestingly,
we noticed important quantitative and qualitative diﬀerences
in the modiﬁcation of cellular polypeptides by either cyPG.
Incorporation of 15d-PGJ2-B was more eﬃcient (Fig. 1B, low-
er panel). In addition, the labeling patterns obtained with the
two biotinylated prostanoids were not identical, as evidenced
in the densitometric proﬁles of the corresponding gel lanes
(Fig. 2A). Some of the bands showing more prominent diﬀer-
ences are marked by arrowheads. To verify these diﬀerences we
performed 2D-electrophoresis (Fig. 2B). This analysis clearly
showed the presence of biotin-positive spots common to 15d-
PGJ2-B and PGA1-B-treated cells (marked by arrowheads),
along with spots selective of either condition. Some of the
spots which consistently showed selectivity or were labeled
with diﬀerent intensity are highlighted in boxes. These observa-
tions indicate that the eﬃciency and the selectivity of protein
modiﬁcation by PGA1-B and 15d-PGJ2-B in intact cells dis-
play important diﬀerences.3.2. Binding of 15d-PGJ2-B and PGA1-B to NIH-3T3 proteins in
cell-free extracts
The diﬀerences shown above could be due to several factors
including disparities in the reactivity of the two prostanoids to-
wards cellular thiols or in their intracellular accumulation. To
explore these possibilities we ﬁrst performed a labeling assay
using cell-free extracts. As shown in Fig. 3, both the quantita-
tive and qualitative diﬀerences in protein labeling observed in
intact cells were markedly reduced when cell lysates were trea-
ted with 15d-PGJ2-B or with PGA1-B. These observations sug-
gest that factors determined by cell integrity are important for
the diﬀerential modiﬁcation of proteins by cyPG.3.3. Eﬀect of GSH on cyPG binding to proteins
The intracellular concentration of GSH has been proposed
to be an important factor for the biological eﬀects of cyPG.
We therefore explored whether GSH could aﬀect the intensity
or selectivity of protein modiﬁcation by biotinylated cyPG. As
stated above, labeling of proteins present in lysates was similar
with the two cyPG in the absence of added GSH (Fig. 4).
Addition of GSH at concentrations in the range of those pres-
ent in cells clearly reduced the incorporation of biotinylated
cyPG into proteins in cell-free lysates. Noteworthy, this inhibi-
tion was more marked in the case of PGA1-B. In addition,
GSH reduced the incorporation of biotinylated cyPG more po-
tently in certain polypeptide bands (marked by arrowheads in
Fig. 2. Qualitative diﬀerences in the binding of biotinylated cyPG to
cellular polypeptides in NIH-3T3. (A) Total cell lysates from control
cells or cells treated with 5 lM 15d-PGJ2-B or 60 lM PGA1-B were
analyzed by SDS–PAGE and Western blot. The intensity proﬁles
obtained for each lane are shown (lower panel). Arrowheads mark the
polypeptide bands which displayed more evident diﬀerences in biotin
signal intensity. (B) Cell lysates were analyzed by 2D-electrophoresis
and Western blot. Results shown are representative of ﬁve analysis for
every condition. Endogenous biotinylated proteins are marked by
arrows. Spots consistently appearing in both experimental conditions
are marked by arrowheads and the regions where selective spots are
detected are depicted by boxes.
Fig. 3. Incorporation of biotinylated cyPG into NIH-3T3 proteins in
cell-free extracts. Total cell lysates were incubated with the indicated
concentrations of 15d-PGJ2-B or PGA1-B and biotin incorporation
was assessed as described in Fig. 1. Results are average val-
ues ± S.E.M. of ﬁve assays (\P < 0.05 by t test).
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biotinylated cyPG was 15d-PGJ2-B or PGA1-B. These obser-
vations suggest that GSH levels may contribute to the dif-
ferential modiﬁcation of cellular proteins by 15d-PGJ2-B or
PGA1-B. Therefore we tested whether GSH levels could inﬂu-
ence cyPG protein modiﬁcation in intact cells. Pre-treatmentof NIH-3T3 ﬁbroblasts with the GSH synthesis inhibitor
buthionine sulfoximine (BSO), increased the intensity of pro-
tein labeling by biotinylated cyPG in a dose-dependent fashion
(Fig. 5A and B). Interestingly, this increase was proportionally
more marked in the case of low concentrations of PGA1-B (see
quantitation in Fig. 5C). In addition, inhibition of GSH bio-
synthesis induced a more prominent increase in the labeling
of some polypeptide bands, thus altering the labeling patterns.
To better observe these diﬀerences we performed 2D-electro-
phoresis (Fig. 6). The intensity of several spots clearly in-
creased after BSO treatment. Some of these spots are
marked by arrowheads in Fig. 6. Conversely, pre-incubation
of ﬁbroblasts with N-acetyl-L-cysteine to increase cellular thiol
content, reduced the incorporation of biotinylated cyPG into
cellular proteins, more intensely in the case of PGA1-B
(Fig. 5D). Taken together these observations suggest that a dif-
ferential reactivity in the presence of soluble thiols, such as
GSH, contributes to the selectivity of protein modiﬁcation
by cyPG.4. Discussion
Biological actions of cyPG are due in part to their ability to
covalently bind to cellular proteins. Several recent studies have
sought to modify cyPG structure in order to obtain higher
antiinﬂammatory or antiproliferative potency [16,17]. How-
ever, the speciﬁcity of protein modiﬁcation by diverse cyPG
has not been previously addressed. Here we have observed that
15d-PGJ2-B is more eﬀective than PGA1-B at modifying cellu-
lar proteins. This is in agreement with the biological potency of
their parent compounds. Typically, ﬁve to ten fold higher con-
centrations of PGA1 are required to elicit eﬀects comparable to
those of 15d-PGJ2 on IKK activity [8], NF-jB DNA binding
Fig. 4. Eﬀect of GSH on binding of biotinylated cyPG to proteins in vitro. (A) Cell lysates were incubated with 10 lM biotinylated cyPG in the
absence or presence of 2 mM GSH and biotin labeling was detected as above. Polypeptides showing intense inhibition of cyPG incorporation in the
presence of GSH are indicated by arrowheads. The blot shown is representative of four assays. (B) Densitometric proﬁles obtained for each lane.
Fig. 5. Modulation of cellular GSH levels aﬀects binding of biotinylated cyPG to proteins in cells. Cells were pre-incubated with BSO (at 0, 50 or
100 lM) in serum-free medium for 16 h, before treatment with 15d-PGJ2-B (A) or PGA1-B (B) at the indicated concentrations for 2 h. Incorporation
of biotinylated cyPG into cellular proteins was assessed by Western blot. The biotin signal was quantitated by image scanning and results are shown
in (C). (D) NIH-3T3 cells were incubated with 5 mM N-acetyl-L-cysteine (NAC) for 16 h. Subsequent incubation with 15d-PGJ2-B (5 lM) or PGA1-
B (60 lM), was performed in fresh medium without NAC. Results shown are representative of three experiments with similar results.
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incubation of intact cells with either biotinylated analog results
in a diﬀerent pattern of polypeptide labeling, consisting of
common and selectively modiﬁed bands. Several factors couldcontribute to this selectivity including diﬀerent permeability or
intracellular distribution or alterations in protein expression
induced by the various treatments. Our results identify GSH
levels as an important factor inﬂuencing the potency and selec-
Fig. 6. 2D-electrophoresis analysis of biotinylated cyPG-modiﬁed proteins in GSH-depleted cells. Total cell lysates from NIH-3T3 cells treated with
5 lM 15d-PGJ2-B or 60 lM PGA1-B after pre-incubation in the absence or presence of 50 lM BSO, as detailed in Fig. 5, were analyzed by 2D-
electrophoresis and Western blot. Results are representative of three analysis.
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and in vitro. This could be related to the formation of GSH-
cyPG adducts, a process which can occur through enzymatic
and non-enzymatic mechanisms and results in a reduction in
the availability of free cyPG for protein modiﬁcation [14]. In
cells, conjugation with GSH also favors cyPG detoxiﬁcation
[20]. These factors can lead to an attenuation of the biological
eﬀects of cyPG [20]. Conversely, GSH depletion has been re-
ported to enhance cyPG eﬀects [21,22]. As it is shown here,
modulation of GSH levels also leads to opposite changes in
the extent of protein modiﬁcation by cyPG. Interestingly,
our results show that PGA1-B binding to proteins is more
dependent on GSH levels, both in vitro and in cells. This
may be due to the fact that single enone cyPG, like PGA1,
form more stable adducts with soluble thiols than dienone
cyPG, like 15d-PGJ2 [14]. This would shift the equilibrium to-
wards GSH-cyPG adduct formation in the case of PGA1-B,
with the consequences outlined above. Noteworthy, early evi-
dence supported a diﬀerential subcellular fate of single enone
and dienone cyPG, with single enone being present as soluble
species in a higher proportion [23]. Although the interaction of
cyPG with soluble thiols is reversible, the binding to cellular
proteins has been proposed to be irreversible under physiolog-
ical conditions [14,24]. Several factors have been postulated to
contribute to the stability of cyPG-protein interactions, includ-
ing the decreased molecular motion of protein biomatrices
[24], the presence of low pKa cysteine residues with a high reac-
tivity, and the nature of the amino acids in the vicinity of the
target cysteines [1]. These factors could also aﬀect the selectiv-
ity of protein modiﬁcation. In summary, our ﬁndings illustrate
the diﬀerential binding to proteins of distinct cyPG and postu-
late a role for their unique reactivity towards GSH in this phe-
nomenon. Identiﬁcation of the proteins susceptible to be
modiﬁed by various cyPG will provide a deeper insight intothe factors that determine their selectivity and help to ascertain
whether target-speciﬁc cyPG can be designed.
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